4-aminopyridine has been researched along with Autoimmune Experimental Myasthenia Gravis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morsch, M | 1 |
| Reddel, SW | 1 |
| Ghazanfari, N | 1 |
| Toyka, KV | 1 |
| Phillips, WD | 1 |
| Mori, S | 1 |
| Kishi, M | 1 |
| Kubo, S | 1 |
| Akiyoshi, T | 1 |
| Yamada, S | 1 |
| Miyazaki, T | 1 |
| Konishi, T | 1 |
| Maruyama, N | 1 |
| Shigemoto, K | 1 |
2 other studies available for 4-aminopyridine and Autoimmune Experimental Myasthenia Gravis
| Article | Year |
|---|---|
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Cholinesterase Inhibitors; Evoked Potential | 2013 |
3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Disease Models, Animal; Female; Mice; Myast | 2012 |